Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 20 New Entrants companies in Ribociclib
by Most Patent Filing In 3 Years in the world in 2018

The Ribociclib top 20 is Discovery PatSnap’ annual ranking of the top 20 Most Patent Filing In 3 Years Ribociclib New Entrants in the world. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2018, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
Ribociclib (trade name Kisqali) is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals.
#
Company Name
Region
Tech Topics
Total
1
Patent: 3
2
Contract research organization,Health care,Liposome,
...[+2]
Patent: 2
3
Patent: 2
4
Patent: 2
5
Pennsylvania, United States
Trade partner,Corporate social responsibility,Medicine,
...[+2]
Patent: 2
6
Patent: 2
7
Noord-Brabant, Netherlands
Patent: 2
8
Patent: 2
9
Patent: 2
10
Active ingredient,Radioimmunoassay,Diagnostic microbiology,
...[+2]
Patent: 1
11
New Jersey, United States
Medicine,Prescription drug,Cardiovascular agent,
...[+2]
Patent: 1
12
Patent: 1
13
Patent: 1
14
Patent: 1
15
Patent: 1
16
Patent: 1
17
Patent: 1
18
New York, United States
Health care,Clinical trial,Drug,
...[+2]
Patent: 1
19
Shanghai Yaoda Biotechnology Co., Ltd.
Patent: 1
20
Tennessee, United States
Patent: 1
Page generation time: Jul 07 2025